Current Understanding of Primary Biliary Cholangitis

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2020 Dec 3

PMID 33264835

Citations 46

Authors

Atsushi Tanaka

Affiliations

Soon will be listed here.

Abstract

Primary biliary cholangitis (PBC) causes chronic and persistent cholestasis in the liver, eventually resulting in cirrhosis and hepatic failure without appropriate treatment. PBC mainly develops in middle-aged women, but it is also common in young women and men. PBC is considered a model of autoimmune disease because of the presence of diseasespecific autoantibodies, that is, antimitochondrial antibodies (AMAs), intense infiltration of mononuclear cells into the bile ducts, and a high prevalence of autoimmune diseases such as comorbidities. Histologically, PBC is characterized by degeneration and necrosis of intrahepatic biliary epithelial cells surrounded by a dense infiltration of mononuclear cells, coined as chronic non-suppurative destructive cholangitis, which leads to destructive changes and the disappearance of small- or medium-sized bile ducts. Since 1990, early diagnosis with the detection of AMAs and introduction of ursodeoxycholic acid as first-line treatment has greatly altered the clinical course of PBC, and liver transplantation-free survival of patients with PBC is now comparable to that of the general population.

Citing Articles

Exploration of the Combined Mechanism of Direct and Indirect Effects of Paeoniflorin in the Treatment of Cholestasis.

Zhang W, Wang Z, Sun R, Zeng Y, Chen Y, Hu Q Inflammation. 2025; .

PMID: 39869299 DOI: 10.1007/s10753-025-02245-0.

Alcohol Consumption and Autoimmune Diseases.

Terracina S, Caronti B, Lucarelli M, Francati S, Piccioni M, Tarani L Int J Mol Sci. 2025; 26(2).

PMID: 39859557 PMC: 11766456. DOI: 10.3390/ijms26020845.

Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.

Durazzo M, Ferro A, Navarro-Tableros V, Gaido A, Fornengo P, Altruda F Biomolecules. 2025; 15(1).

PMID: 39858515 PMC: 11763965. DOI: 10.3390/biom15010121.

Probing the Effects of Multisite Mutations in the Lipoic Acid Region of the BCOADC-E2 Protein.

Wang J, Yang M, Wei H, Miao W, Li S, Gao X Int J Mol Sci. 2025; 25(24.

PMID: 39769438 PMC: 11678370. DOI: 10.3390/ijms252413677.

Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies.

Wang W, Lian H, Liang Y, Ye Y, Tam P, Chen Y Cells. 2024; 13(23).

PMID: 39682745 PMC: 11640075. DOI: 10.3390/cells13231997.

References

Lleo A, Bian Z, Zhang H, Miao Q, Yang F, Peng Y . Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS One. 2016; 11(9):e0159612. PMC: 5025177. DOI: 10.1371/journal.pone.0159612. View

Van de Water J, Gershwin M, Leung P, Ansari A, Coppel R . The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. J Exp Med. 1988; 167(6):1791-9. PMC: 2189671. DOI: 10.1084/jem.167.6.1791. View

Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E . Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. DOI: 10.1002/hep.22906. View

Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A . Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol. 2018; 53(10):1151-1158. DOI: 10.1007/s00535-018-1465-z. View

Kremer A, Martens J, Kulik W, Rueff F, Kuiper E, van Buuren H . Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010; 139(3):1008-18, 1018.e1. DOI: 10.1053/j.gastro.2010.05.009. View

Carbone M, Mells G, Alexander G, Westbrook R, Heneghan M, Sandford R . Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2013; 13(4):1110-1111. DOI: 10.1111/ajt.12132. View

Sylvestre P, Batts K, Burgart L, Poterucha J, Wiesner R . Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history. Liver Transpl. 2003; 9(10):1086-93. DOI: 10.1053/jlts.2003.50213. View

Mattalia A, Quaranta S, Leung P, Bauducci M, Van de Water J, Calvo P . Characterization of antimitochondrial antibodies in health adults. Hepatology. 1998; 27(3):656-61. DOI: 10.1002/hep.510270303. View

Arase Y, Tsuruya K, Hirose S, Ogiwara N, Yokota M, Anzai K . Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases. Hepatology. 2019; 71(2):757-759. PMC: 7028030. DOI: 10.1002/hep.30904. View

10.

Tanaka A, Leung P, Gershwin M . The Genetics and Epigenetics of Primary Biliary Cholangitis. Clin Liver Dis. 2018; 22(3):443-455. DOI: 10.1016/j.cld.2018.03.002. View

11.

Harms M, Janssen Q, Adam R, Duvoux C, Mirza D, Hidalgo E . Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Aliment Pharmacol Ther. 2018; 49(3):285-295. PMC: 6590354. DOI: 10.1111/apt.15060. View

12.

Tandon P, Rowe B, Vandermeer B, Bain V . The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007; 102(7):1528-36. DOI: 10.1111/j.1572-0241.2007.01200.x. View

13.

Sanchez E, Levy M, Goldstein R, Fasola C, Tillery G, Netto G . The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation. 2004; 76(11):1583-8. DOI: 10.1097/01.TP.0000090867.83666.F7. View

14.

Beuers U, Gershwin M, Gish R, Invernizzi P, Jones D, Lindor K . Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. Gastroenterology. 2015; 149(6):1627-9. DOI: 10.1053/j.gastro.2015.08.031. View

15.

Hytiroglou P, Gutierrez J, Freni M, Odin J, Stanca C, Merati S . Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: A blind histologic study. Hepatol Res. 2009; 39(6):577-84. PMC: 3127546. DOI: 10.1111/j.1872-034X.2008.00483.x. View

16.

Manousou P, Arvaniti V, Tsochatzis E, Isgro G, Jones K, Shirling G . Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl. 2009; 16(1):64-73. DOI: 10.1002/lt.21960. View

17.

Hirschfield G, Xie G, Lu E, Sun Y, Juran B, Chellappa V . Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun. 2012; 13(4):328-35. PMC: 3360983. DOI: 10.1038/gene.2011.89. View

18.

Kogiso T, Egawa H, Teramukai S, Taniai M, Hashimoto E, Tokushige K . Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study. Hepatol Commun. 2018; 1(5):394-405. PMC: 5721413. DOI: 10.1002/hep4.1037. View

19.

Tanaka A, Mori M, Matsumoto K, Ohira H, Tazuma S, Takikawa H . Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res. 2019; 49(8):881-889. DOI: 10.1111/hepr.13342. View

20.

Cheung A, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield G, Janssen H . Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2015; 43(2):283-93. DOI: 10.1111/apt.13465. View